Abstract:
:Controversial results have been reported concerning the correlation between serum levels of IgM antibodies to hepatitis B core antigen (IgM HBcAb) and the histological activity of chronic hepatitis B. In this study, paired serum samples and liver biopsies were collected from 200 consecutive chronic hepatitis B patients (mean age 39.2 +/- 0.8 years; M:F 154:46; 41 hepatitis B e antigen (HBeAg) positive) and tested for IgM HBcAb using a semiquantitative highly sensitive assay (IMx CORE-M(R)). The severity of liver disease was assessed by the Ishak score, grading the necroinflammatory activity (by using the histology activity index, HAI) and staging the fibrosis. The index values of IgM HBcAb were significantly different among patients with mild (HAI < or = 6), moderate (HAI 7-12) and severe (HAI > or = 13) necroinflammatory activity but the stage of fibrosis was unrelated to the IgM HBcAb. According to the index value of IgM HBcAb, we selected three groups of patients: Group A included 36 patients with an index value below 0.200; Group B, 99 patients with an index value between 0.200 and 0.500; and Group C, 65 patients with an index value over 0.500. The mean HAI grading in Group A was 5.3 +/- 0.4, in Group B it was 7.4 +/- 0.3 and in Group C it was 8.9 +/- 0.4 (f = 16.5, P < 0.0001). A mild HAI grading was observed in 77.8% of Group A, in 47.5% of Group B and in 23.1% of Group C patients; conversely, severe grading was detected in 0% of Group A, in 11.1% of Group B and in 18.5% of Group C patients (P < 0.0001). An index value of IgM HBcAb below 0.200 was 75% predictive of a mild necroinflammatory activity (29% sensitivity and 91.6% specificity) and ruled out a severe activity. Therefore, the quantitative assessment of IgM HBcAb appears to be a useful clinical tool in the prediction of the necroinflammatory activity of chronic hepatitis B. A serum index value of IgM HBcAb consistently below 0.200 could be considered a surrogate marker of remission of hepatitis B virus-induced liver disease.
journal_name
J Viral Hepatjournal_title
Journal of viral hepatitisauthors
Colloredo G,Bellati G,Sonzogni A,Zavaglia C,Fracassetti O,Leandro G,Ghislandi R,Minola E,Ideo Gdoi
10.1046/j.1365-2893.1999.00171.xsubject
Has Abstractpub_date
1999-11-01 00:00:00pages
429-34issue
6eissn
1352-0504issn
1365-2893pii
jvh171journal_volume
6pub_type
杂志文章abstract::Circulating microRNAs (miRNA) have been intensely investigated as biomarkers in disease and therapy. Several studies have identified miR-122 as an important regulator of HCV replication. The effect of new therapies that directly target the HCV replication life cycle on circulating microRNA levels has not been elucidat...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,多中心研究
doi:10.1111/jvh.12470
更新日期:2016-02-01 00:00:00
abstract::This study examined the association between chronic HBV or HCV infection and the risk of extrahepatic cancers. A total of 537 103 adults aged ≥20 years without history of cancer were identified from the Korean National Health Insurance Service-National Sample Cohort between 2003 and 2013. The difference in cancer inci...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.13304
更新日期:2020-09-01 00:00:00
abstract::Chronic infection with the hepatitis C virus is a major health problem. Conventional therapy, with interferon-alpha is effective in only a minority of patients. The failure of current treatments has led to a major initiative to identify new antiviral agents. In the absence of a tissue culture model for hepatitis C inf...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1111/j.1365-2893.1995.tb00066.x
更新日期:1995-01-01 00:00:00
abstract::Serological and biochemical studies indicate that acute HBV infection is resolved in the context of an efficient cell-mediated immune (CMI) response, whereas, chronic infection is characterized by weak to undetectable CMI responses and relatively efficient humoral immunity. Because humoral immunity and CMI are regulat...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.1997.tb00180.x
更新日期:1997-01-01 00:00:00
abstract::We aimed to assess fibrosis with liver stiffness measurement long-term after sustained virological response of chronic hepatitis C and to identify risk factors associated with persisting fibrosis. In this cross-sectional study, patients with chronic hepatitis C and pretreatment advanced fibrosis or cirrhosis treated s...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12879
更新日期:2018-07-01 00:00:00
abstract::The treatment option in chronic hepatitis B (CHB) patients with persistent low-level viremia despite entecavir or tenofovir monotherapy is unclear. This study investigated the development of hepatocellular carcinoma (HCC) or cirrhosis in hepatitis B e antigen (HBeAg)-positive high viral load CHB patients, according to...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12838
更新日期:2018-05-01 00:00:00
abstract::Self-efficacy or confidence in one's ability to successfully engage in goal-directed behaviour has been shown to influence medication adherence across many chronic illnesses. In the present study, we investigated the psychometric properties of a self-efficacy instrument used during treatment for chronic hepatitis C vi...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2011.01550.x
更新日期:2012-05-01 00:00:00
abstract::Hepatitis delta virus (HDV) infection is a usually severe type of viral hepatitis associated with increased mortality and rapid evolution to cirrhosis. Currently, treatment is limited to extended interferon administration and measurement of HDV RNA blood levels is essential to judge the response. The aim of this study...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12000
更新日期:2013-04-01 00:00:00
abstract::Despite the recent progress in antiviral therapy of chronic hepatitis B, clinical experience has shown that antiviral drug resistance is inevitable with the administration of nucleoside analog monotherapy. The long-term persistence of the viral genome in infected cells and the high rate of spontaneous mutation is the ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1111/j.1365-2893.2007.00915.x
更新日期:2007-11-01 00:00:00
abstract::Increased infiltration of lymphocytes and induction of damage and destruction of hepatocytes by these lymphocytes are characteristic features of chronic viral hepatitis. As chemokines attract lymphocytes to inflamed tissues, we studied macrophage inflammatory protein (MIP)-3alpha, a CC chemokine, in chronic viral hepa...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1046/j.1365-2893.2002.00354.x
更新日期:2002-05-01 00:00:00
abstract::Hepatitis B virus (HBV) infection is associated with many extrahepatic malignancies, but its association with and impact on ovarian cancer has not been examined. We therefore examined the prevalence of HBV infection among women with primary ovarian carcinoma in an endemic area, and whether this impacts the presentatio...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.13250
更新日期:2020-05-01 00:00:00
abstract::A significant proportion of chronic hepatitis C patients fails to achieve sustained virologic response even after treatment with the current, more potent, combination of pegylated interferon-alpha (IFNa) plus ribavirin. Such patients represent a rather heterogeneous group and may be divided initially into relapsers an...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1111/j.1365-2893.2004.00522.x
更新日期:2004-07-01 00:00:00
abstract::In a previously reported randomized controlled trial of interferon-alpha (IFN-alpha) for chronic hepatitis B, we found a significant difference in response between Chinese adults with elevated vs normal pretreatment aminotransferase (ALT) levels. The aim of this study was to determine the correlation between serum hep...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1046/j.1365-2893.1998.00098.x
更新日期:1998-05-01 00:00:00
abstract::Peripheral blood mononuclear cells (PBMC) from chronic hepatitis C virus-infected persons can harbour viral variants that are not detected in plasma samples. We explored the presence and persistence of HCV genotypes in plasma and PBMC cultures from 25 HCV-monoinfected and 25 HIV/HCV-coinfected patients with haemophili...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12363
更新日期:2015-07-01 00:00:00
abstract::To evaluate the cost-effectiveness of ledipasvir/sofosbuvir (LDV/SOF) in treatment-naïve patients with chronic hepatitis C (CHC) genotype 1 (GT1) in the absence or mild fibrosis (F0-F1) versus advanced fibrosis (F2-F4), from the perspective of the Spanish Health System. A Markov model was developed to simulate disease...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.12704
更新日期:2017-09-01 00:00:00
abstract::The risk of developing hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) is reduced by antiviral therapy. Here, we evaluated the chronological trends in HCC development risk starting in 2007, when entecavir reimbursement was first initiated in South Korea. Treatment-naïve patients with chronic hepatitis B...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.13384
更新日期:2020-12-01 00:00:00
abstract::Among individuals with chronic hepatitis C virus (HCV) infection, approximately 30% of patients show persistently normal alanine aminotransferase (PNALT). Individuals with PNALT have been historically excluded from antiviral treatment. However, some studies have reported sudden worsening of disease in patients with PN...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2010.01403.x
更新日期:2011-07-01 00:00:00
abstract::Favourable efficacy and safety profiles for simeprevir in combination with pegylated interferon alpha (PEG-IFNα) and ribavirin (triple therapy) have been shown in clinical trials. This study was carried out to evaluate the effectiveness of simeprevir-based triple therapy for patients with prior telaprevir treatment fa...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,多中心研究
doi:10.1111/jvh.12427
更新日期:2015-12-01 00:00:00
abstract::Ultrasound-based elastography and serum indexes have been individually validated as noninvasive methods for staging liver fibrosis in chronic viral hepatitis. We aimed to compare the accuracy of transient elastography (TE), shear wave elastography (SWE), aspartate aminotransferase to platelet index (APRI) and Fibrosis...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.13246
更新日期:2020-04-01 00:00:00
abstract::With the advent of direct-acting antivirals (DAAs), the treatment of chronic hepatitis C virus (HCV) infection (CHC) has been revolutionized. Modern interferon- and potentially also ribavirin-free combinations consisting of 2 or 3 direct-acting antivirals (DAA) promise sustained virological response rates (SVR) of abo...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1111/jvh.12348
更新日期:2015-01-01 00:00:00
abstract::Peripheral blood mononuclear cells (PBMCs) from 45 treatment naïve, HIV-negative, chronically hepatitis C virus (HCV)-infected patients were analyzed for the presence of HCV RNA. Viral RNA was detected in 73% of the studied patients. Single-strand conformation polymorphism assays and sequence analysis of the HCV 5'unt...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2009.01112.x
更新日期:2009-09-01 00:00:00
abstract::Assessment and treatment for hepatitis C virus (HCV) in the community remains low. We evaluated factors associated with HCV specialist assessment and treatment in a cross-sectional study to evaluate treatment considerations in a sample of 634 participants with self-reported HCV infection in New South Wales, Australia....
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2010.01370.x
更新日期:2011-04-01 00:00:00
abstract::Although long-term antiviral treatment with nucleos(t)ide analogs (NAs) can lead to histological improvement in patients with chronic hepatitis B (CHB), a substantial proportion of patients still fail to achieve regression of fibrosis. Here, we investigated whether peginterferon alpha (Peg-IFNα) add-on therapy had ben...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/jvh.13152
更新日期:2019-07-01 00:00:00
abstract::Autoantibodies are commonly detected in chronic hepatitis C (HCV) but their significance remains uncertain. We assessed the prevalence of anti-nuclear (ANA) and anti-smooth muscle (ASM) antibodies within a cohort of 963 treatment-naïve HCV patients. We also assessed for differences between autoantibody-positive and au...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2008.01035.x
更新日期:2009-05-01 00:00:00
abstract::Extremely low levels of serum hepatitis C virus (HCV) RNA can be detected by COBAS TaqMan HCV test. To investigate whether the COBAS TaqMan HCV test is useful for measuring rapid virological response (RVR) and early virological response (EVR) to predict sustained virological response (SVR), we compared the virological...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2010.01409.x
更新日期:2011-07-01 00:00:00
abstract::Drug users with chronic hepatitis C virus (HCV) infection are frequently co-infected with human immunodeficiency virus-1 (HIV-1), but it is still not clear whether HIV-1 worsens the natural history of hepatitis C. To investigate this, we conducted a multicentre observational study in 163 drug addicts with histological...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1046/j.1365-2893.2000.00230.x
更新日期:2000-07-01 00:00:00
abstract::The aim of this study was to evaluate the pharmacokinetic profile of daclatasvir (DCV) and asunaprevir (ASV) dual therapy in haemodialysis patients infected with hepatitis C virus (HCV). Eighteen haemodialysis patients and 54 patients with normal renal function were treated with DCV and ASV dual therapy for 24 weeks. ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,多中心研究
doi:10.1111/jvh.12553
更新日期:2016-11-01 00:00:00
abstract::We conducted an analytical review of 194 full papers on interferon (IFN) therapy for chronic hepatitis C to evaluate current methodology (i.e. study design, criteria for evaluating the efficacy of therapy and predictors of response). Of the papers evaluated, 64 were randomized controlled trials (RCT), 40 were non-rand...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,评审
doi:10.1046/j.1365-2893.2000.00214.x
更新日期:2000-05-01 00:00:00
abstract::The triglycerides × glucose (TyG) index is a recently proposed surrogate marker of insulin resistance (IR), calculated from fasting plasma triglyceride and glucose concentrations. We tested the host and viral factors associated with Tyg and homeostasis model assessment (HOMA) scores, comparing their associations with ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章
doi:10.1111/j.1365-2893.2011.01439.x
更新日期:2011-07-01 00:00:00
abstract::Peginterferon alpha-2a (40 kDa) plus ribavirin is effective at achieving sustained viral response compared with no treatment in patients with chronic hepatitis C (CHC) and persistently normal aminotransferase levels (PNALT). The cost-effectiveness of treating CHC in the setting of PNALT has not been assessed. Disease ...
journal_title:Journal of viral hepatitis
pub_type: 杂志文章,随机对照试验
doi:10.1111/j.1365-2893.2005.00700.x
更新日期:2006-06-01 00:00:00